Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465224) titled 'A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus' on March 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Alnylam Pharmaceuticals
Condition:
Type 2 Diabetes Mellitus (T2DM)
Intervention:
Drug: ALN-4324
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: January 15, 2026
Target Sample Size: 40
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials....